https://www.nasdaq.com/press-release/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2022
https://www.nasdaq.com/press-release/akebia-therapeutics-to-present-at-40th-annual-j.p.-morgan-healthcare-conference-2022
https://www.nasdaq.com/press-release/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-11
https://www.nasdaq.com/press-release/akebia-therapeutics-announces-participation-in-upcoming-investor-conferences-2021-11
https://www.nasdaq.com/press-release/akebia-therapeutics-to-present-at-jefferies-london-healthcare-conference-2021-11-15
https://www.nasdaq.com/press-release/akebia-therapeutics-reports-third-quarter-2021-financial-results-and-highlights
https://www.nasdaq.com/press-release/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2021-9
https://www.nasdaq.com/press-release/akebia-therapeutics-appoints-ron-frieson-healthcare-operations-leader-to-board-of
https://www.nasdaq.com/press-release/akebia-announces-otsukas-submission-of-initial-marketing-authorization-application-to
https://www.nasdaq.com/press-release/akebia-therapeutics-to-report-third-quarter-2021-financial-results-and-highlight
https://www.nasdaq.com/press-release/statement-from-akebia-therapeutics-regarding-litigation-against-centers-for-medicare
https://www.nasdaq.com/press-release/akebia-announces-vadadustat-efficacy-and-safety-data-to-be-presented-at-american
https://www.nasdaq.com/press-release/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2021-8
https://www.nasdaq.com/press-release/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2021-7
https://www.nasdaq.com/press-release/akebia-therapeutics-announces-september-2021-investor-conference-schedule-2021-09-01
https://www.nasdaq.com/press-release/akebia-therapeutics-reports-second-quarter-2021-financial-results-and-highlights
https://www.nasdaq.com/press-release/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2021-6
https://www.nasdaq.com/press-release/akebia-therapeutics-to-report-second-quarter-2021-financial-results-and-discuss
https://www.nasdaq.com/press-release/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2021-5
https://www.nasdaq.com/press-release/akebia-therapeutics-announces-presentations-at-era-edta-virtual-congress-2021-2021-06
https://www.nasdaq.com/press-release/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2021-4
https://www.nasdaq.com/press-release/akebia-and-otsuka-announce-fda-acceptance-for-filing-of-new-drug-application-for
https://www.nasdaq.com/press-release/akebia-reports-first-quarter-2021-financial-results-and-highlights-recent-company
https://www.nasdaq.com/press-release/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2021-3
https://www.nasdaq.com/press-release/new-england-journal-of-medicine-publishes-results-of-global-phase-3-clinical-program
https://www.nasdaq.com/press-release/akebia-therapeutics-to-report-first-quarter-2021-financial-results-and-discuss-recent
https://www.nasdaq.com/press-release/akebia-therapeutics-to-present-at-20th-annual-needham-virtual-healthcare-conference
https://www.nasdaq.com/press-release/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2021-2
https://www.nasdaq.com/press-release/akebia-submits-new-drug-application-nda-to-the-fda-for-vadadustat-for-the-treatment
https://www.nasdaq.com/press-release/akebia-therapeutics-announces-poster-presentations-and-educational-symposium-at
https://www.nasdaq.com/press-release/akebia-therapeutics-announces-approval-for-additional-indication-of-rionar-ferric
https://www.nasdaq.com/press-release/akebia-therapeutics-celebrates-world-kidney-day-and-national-kidney-month-2021-03-11
https://www.nasdaq.com/press-release/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2021-1
https://www.nasdaq.com/press-release/akebia-therapeutics-to-present-at-h.c.-wainwright-global-life-sciences-conference
https://www.nasdaq.com/press-release/akebia-reports-fourth-quarter-and-full-year-2020-financial-results-and-provides
https://www.nasdaq.com/press-release/akebia-therapeutics-appoints-leanne-m.-zumwalt-dialysis-industry-leader-to-board-of
https://www.nasdaq.com/press-release/akebia-therapeutics-to-report-fourth-quarter-and-full-year-2020-financial-results-and
https://www.nasdaq.com/press-release/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2021-0
https://www.nasdaq.com/press-release/akebia-therapeutics-to-present-at-h.c.-wainwright-bioconnect-2021-conference-2021-01
https://www.nasdaq.com/press-release/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2021
https://www.nasdaq.com/press-release/akebia-therapeutics-to-present-at-39th-annual-j.p.-morgan-healthcare-conference-2021
https://www.nasdaq.com/press-release/akebiashares-program%3a-current-approaches-for-managing-hyperphosphatemia-and-caring
https://www.nasdaq.com/press-release/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-10
https://www.nasdaq.com/press-release/akebia-therapeutics-to-participate-in-piper-sandler-32nd-annual-virtual-healthcare
https://www.nasdaq.com/press-release/akebia-therapeutics-ranked-10th-fastest-growing-company-in-north-america-on-deloittes
https://www.nasdaq.com/press-release/akebia-announces-manuscript-highlighting-global-phase-3-inno2vate-program-rationale
https://www.nasdaq.com/press-release/akebia-reports-third-quarter-2020-financial-results-and-recent-business-updates-2020
https://www.nasdaq.com/press-release/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2020-9
https://www.nasdaq.com/press-release/akebia-therapeutics-to-report-third-quarter-2020-financial-results-and-discuss-recent
https://www.nasdaq.com/press-release/akebia-presents-results-from-its-inno2vate-global-phase-3-program-demonstrated
https://www.nasdaq.com/press-release/akebia-to-present-global-phase-3-vadadustat-data-at-american-society-of-nephrology
https://www.nasdaq.com/press-release/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2020-8
https://www.nasdaq.com/press-release/akebia-therapeutics-announces-september-2020-investor-conference-schedule-2020-09-08
https://www.nasdaq.com/press-release/akebia-therapeutics-announces-top-line-results-from-its-pro2tect-global-phase-3
https://www.nasdaq.com/press-release/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2020-7
https://www.nasdaq.com/press-release/akebia-therapeutics-announces-first-commercial-launch-of-vafseotm-vadadustat-tablets
https://www.nasdaq.com/press-release/akebia-reports-second-quarter-2020-financial-results-2020-08-10
https://www.nasdaq.com/press-release/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2020-6
https://www.nasdaq.com/press-release/akebia-therapeutics-to-report-second-quarter-2020-financial-results-2020-08-03
https://www.nasdaq.com/press-release/akebia-announces-initiation-of-investigator-sponsored-study-evaluating-vadadustat-for
https://www.nasdaq.com/press-release/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2020-5
https://www.nasdaq.com/press-release/akebia-therapeutics-announces-approval-of-vadadustat-in-japan-for-the-treatment-of
https://www.nasdaq.com/press-release/akebia-therapeutics-launches-akebiashares-a-peer-to-peer-educational-program-series
https://www.nasdaq.com/press-release/akebia-therapeutics-announces-new-chief-financial-officer-2020-06-18
https://www.nasdaq.com/press-release/akebia-therapeutics-announces-data-on-different-dosing-regimens-of-ferric-citrate-for
https://www.nasdaq.com/press-release/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2020-4
https://www.nasdaq.com/press-release/akebia-therapeutics-to-present-at-jefferies-virtual-global-healthcare-conference-2020
https://www.nasdaq.com/press-release/akebia-therapeutics-announces-change-to-virtual-annual-meeting-of-stockholders-2020
https://www.nasdaq.com/press-release/akebia-therapeutics-announces-full-exercise-of-underwriters-option-to-purchase
https://www.nasdaq.com/press-release/akebia-therapeutics-announces-collaboration-partners-submission-of-supplemental-new
https://www.nasdaq.com/press-release/akebia-therapeutics-announces-pricing-of-upsized-public-offering-of-common-stock-2020
https://www.nasdaq.com/press-release/akebia-therapeutics-announces-proposed-public-offering-of-common-stock-2020-05-11
https://www.nasdaq.com/press-release/akebia-therapeutics-to-present-at-rbc-capital-markets-global-healthcare-virtual
https://www.nasdaq.com/press-release/akebia-announced-positive-top-line-results-from-global-phase-3-program-of-vadadustat
https://www.nasdaq.com/press-release/akebia-therapeutics-announces-positive-top-line-results-from-global-phase-3-program
https://www.nasdaq.com/press-release/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2020-3
https://www.nasdaq.com/press-release/akebia-therapeutics-to-report-first-quarter-2020-financial-results-and-discuss-recent
https://www.nasdaq.com/press-release/akebia-therapeutics-appoints-myles-wolf-m.d.-m.m.sc.-chief-of-nephrology-and
https://www.nasdaq.com/press-release/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2020-2
https://www.nasdaq.com/press-release/akebia-therapeutics-to-present-research-at-nkf-2020-spring-clinical-meetings-live
https://www.nasdaq.com/press-release/a-message-from-akebia-therapeutics-inc.s-chief-executive-officer-to-our-patients
https://www.nasdaq.com/press-release/akebia-therapeutics-reports-fourth-quarter-and-full-year-2019-financial-results-and
https://www.nasdaq.com/press-release/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2020-1
https://www.nasdaq.com/press-release/akebia-therapeutics-to-report-fourth-quarter-and-full-year-2019-financial-results-and
https://www.nasdaq.com/press-release/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2020-0
https://www.nasdaq.com/press-release/akebia-therapeutics-to-present-at-the-38th-annual-j.p.-morgan-healthcare-conference
https://www.nasdaq.com/press-release/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2020
https://www.nasdaq.com/press-release/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2019-3
https://www.nasdaq.com/press-release/akebia-therapeutics-to-present-at-upcoming-investor-conferences-2019-11-21
https://www.nasdaq.com/press-release/akebia-secures-%24100-million-non-dilutive-term-loan-financing-reports-third-quarter
https://www.nasdaq.com/press-release/akebia-announces-positive-52-week-efficacy-and-safety-data-for-vadadustat-from-two
https://www.nasdaq.com/press-release/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2019-2
https://www.nasdaq.com/press-release/akebia-therapeutics-to-report-third-quarter-2019-financial-results-and-discuss-recent
https://www.nasdaq.com/press-release/akebia-announces-nine-abstracts-accepted-for-presentation-at-the-american-society-of
https://www.nasdaq.com/press-release/akebia-files-lawsuit-against-cms-for-2018-action-rescinding-medicare-part-d-coverage
https://www.nasdaq.com/press-release/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2019-1
